Issue Date: March 28, 2016 | Web Date: March 25, 2016
BMS to buy start-up Padlock
Bristol-Myers Squibb will pay up to $600 million to acquire Padlock Therapeutics, a biotech firm developing small molecules for autoimmune diseases.
Padlock, which C&EN named one of 10 Start-ups to Watch last year, takes a contrarian approach to autoimmunity. Whereas drug development for diseases such as arthritis and lupus mostly focuses on dampening the activity of an immune system gone awry, Padlock believes immune cells are actually responding to normal enzymes called . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society